IP Library Patent Application 17911346
Patent Application
App. No. 17/911,346

TREATMENT OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS AND COMPOUNDS FOR SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/911,346
Abstract

The present invention relates to the treatment of disorders associated with oxidative stress including neuropathic pain and small synthetically derived compounds for treating such disorders.

Claims (77)

1 . A method of treating disorders associated with oxidative stress including the step of administering to a subject in need thereof a compound of formula (I):

wherein

R 1 is selected from C 1 -C 3 alkyl;

R 2 represents:

where X is selected from OH, OX 1 , CH 2 C(O)X 2 , C(O)X 2 , CHCHC(O)X 2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted amino and optionally substituted thio; and

wherein X 1 is selected from optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkyl, optionally substituted amino and optionally substituted thio; and

wherein X 2 is selected from OH, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted amino and optionally substituted thio;

or a pharmaceutically acceptable salt, solvate, or isomer thereof.

2 . A method according to claim 1 wherein the treatment is selected from treating vascular diseases, high cholesterol, stroke, heart failure, and hypertension; cancer; neurodegenerative diseases; diabetes; pain disorders; multiple sclerosis; kidney disease; rheumatoid arthritis; sepsis; respiratory distress syndrome; and metabolic disorders, such as mitochondrial diseases, lipid metabolism disorders, and DNA repair-deficiency disorders, COPD, and CKD.

3 . A method according to claim 1 , wherein treatment of the disorder associated with oxidative stress is through site directed target engagement of the NRF2 pathway.

4 . A method according to claim 1 , wherein the treatment is the treatment of pain, preferably neuropathic pain.

5 . A method according to claim 4 , wherein the treatment of neuropathic pain is the treatment of peripheral neuropathic pain.

6 . A method according to claim 1 , wherein the compound of formula (I) is as represented by formula (Ia):

where R 1 is C 1 -C 3 alkyl and

where R 2 is selected from:

a)

b) optionally substituted C 1 -C 12 alkyl

c) optionally substituted heterocyclyl

d) optionally substituted heteroaryl

e)

f)

g)

h)

and

i)

wherein R 3 is selected from OH, CI, F, CF 3 , CN, OCF 3 , optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted acyl, optionally substituted heterocyclyl, optionally substituted alkenyl, optionally substituted heteroaryloxy, optionally substituted aryloxy, optionally substituted heterocyclyloxy, optionally substituted alkenyloxy, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted sulfinyl, and optionally substituted sulfonyl.

n is an integer selected from 0 to 3;

R 4 is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;

R 5 is selected from optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted acyl, optionally substituted heterocyclyl, optionally substituted alkenyl, optionally substituted heteroaryloxy, optionally substituted aryloxy, optionally substituted heterocyclyloxy, optionally substituted alkenyloxy, and optionally substituted cycloalkyl;

R 6 and R 7 are independently selected from H, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl and optionally substituted arylalkyl; and

R 8 is selected from optionally substituted alkyl, optionally substituted aryl, and optionally and substituted arylalkyl.

7 . A method according to claim 6 , wherein the compound of Formula (Ia) is selected from a compound of Formula (Ia)(a-e).

8 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(a).

9 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(b).

10 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(c).

11 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(d).

12 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(e).

13 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(f).

14 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(g).

15 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(h).

16 . A method according to claim 6 , wherein the compound of Formula (Ia) is a compound of Formula (Ia)(i).

17 . A method according to claim 6 , wherein the compound of formula (Ia) is compound of (Ia)(e):

or pharmaceutically acceptable salts thereof:

where R 1 is C 1 -C 3 alkyl and

where R 2 is:

e)

wherein R 4 is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl.

18 . A method according to claim 17 , wherein R 4 is selected from H, C 1 -C 8 substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl.

19 . A method according to claim 18 , wherein R 4 is selected from H and C1-C8 alkyl or wherein R 4 is selected from H and C1-C3 alkyl or wherein R 4 is H or C1-C2 alkyl or R 4 is C1-C2 alkyl, or R 4 is C1 alkyl, or R 4 is C2 alkyl or R 4 is H.

20 . A method according to claim 19 wherein R 4 is a salt form selected from K, Li, Na.

21 . A method according to claim 1 wherein the compound of Formula (I) is selected from:

22 . A compound of formula (II)

or a pharmaceutically acceptable salt thereof:

where R 1′ is C 1 -C 3 alkyl and

where R 2′ is selected from:

a′)

b′) optionally substituted C 2 -C 10 alkyl

c′) optionally substituted heterocyclyl

d′) optionally substituted heteroaryl

e′)

f′)

g′)

h′)

 and

i′)

wherein R 3′ is selected from OH, CI, F, CF 3 , CN, OCF 3 , optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted acyl, optionally substituted heterocyclyl, optionally substituted alkenyl, optionally substituted heteroaryloxy, optionally substituted aryloxy, optionally substituted heterocyclyloxy, optionally substituted alkenyloxy, optionally substituted cycloalkyl, optionally substituted cycloalkyloxy, optionally substituted sulfinyl, and optionally substituted sulfonyl;

m is an integer selected from 1 to 3;

provided that when m is 1, R 3′ is not methyl, OH, NO 2 or methoxy;

R 4′ is selected from optionally substituted C 4 -C 8 alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl;

R 5′ is selected from optionally substituted alkyl, optionally substituted C 2 -C 6 alkoxy, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted acyl, optionally substituted heterocyclyl, optionally substituted alkenyl, optionally substituted heteroaryloxy, optionally substituted aryloxy, optionally substituted heterocyclyloxy, optionally substituted alkenyloxy, and optionally substituted cycloalkyl;

R 6′ and R 7′ are independently selected from H, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl and optionally substituted arylalkyl; provided that when one of R 6′ and R 7′ is H the other is not benzyl; and

R 8′ is selected from optionally substituted alkyl, optionally substituted aryl, and optionally and substituted arylalkyl.

23 . A compound according to claim 22 wherein the compound is selected from compounds of Formula (II)(e′) wherein R4′ is selected from optionally substituted C4-C8 alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl.

24 . A compound according to claim 22 wherein the compound is selected from compounds of Formula (II)(e′) wherein R4′ is selected from optionally substituted aryl.

25 . A compound according to claim 22 wherein the compound is selected from compounds of Formula (II)(e′) wherein R4′ is selected from optionally substituted heteroaryl.

26 . A compound according to claim 23 wherein the compound is selected from compounds of Formula (II)(e′) wherein R4′ is selected from optionally substituted heterocycyl.

27 . A compound according to claim 22 selected from:

Assignments (3)
NUNC PRO TUNC ASSIGNMENT Recorded Jun 2, 2026
From: THE UNIVERSITY OF ADELAIDE
To: ADELAIDE UNIVERSITY
Reel/Frame 075843/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2024
From: GRACE, PETER M.; LI, JIAHE
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 067301/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2023
From: AVERY, THOMAS; ABELL, ANDREW; TURNER, DION
To: THE UNIVERSITY OF ADELAIDE
Reel/Frame 063778/0986 →